By using two independent techniques, we showed that, as in airways, therapeutic doses of vardenafil are able to target in the GI tract, predominantly affected in CF, multiple molecular defects caused by the F508del-CFTR mutation. This evidence concerns the gene CFTR and cystic fibrosis.